Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 5/20 | 0.43 |
| ▸ | MTOR | P42345 | 10/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10331367 | 0.86 | NR3C1 (0.40) | GRIN2BMTORPIK3CANR3C1PGR | |
| SCHEMBL10332009 | 0.84 | TP53 (0.42) | GRIN2BMTORPIK3CACTSKCTSC | |
| SCHEMBL10331956 | 0.83 | MEN1 (0.49) | GRIN2BCTSKCTSCMEN1NPC1 | |
| SCHEMBL10332013 | 0.79 | HDAC4 (0.46) | GRIN2BGRIN1MEN1NPC1RAB9A | |
| SCHEMBL10331985 | 0.76 | HPGD (0.53) | GRIN2BMTORPIK3CAGRIN1MEN1 | |
| SCHEMBL10332046 | 0.76 | GRIN2B (0.51) | GRIN2BMTORPIK3CAGRIN1MEN1 | |
| SCHEMBL10331987 | 0.75 | ALDH1A1 (0.52) | GRIN2BMTORPIK3CAGRIN1 | |
| SCHEMBL12673350 | 0.75 | HSD17B1 (0.50) | GRIN2BCTSKCTSCMEN1NPC1 | |
| SCHEMBL10331963 | 0.73 | SMN1; SMN2 (0.42) | GRIN2BMTORPIK3CAMEN1NPC1 | |
| SCHEMBL15218738 | 0.73 | CES2 (0.53) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222247-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-20100004219-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPABETA ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004219-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPABETA ACTIVITY AND USE THEREOF | NR3C1, NFRKB, RELA | GRIN2B 440/4885MTOR 1418/4885PIK3CA 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.